Investing in a higher-for-longer world: tech, commodities, or both?
Parts of the mega cap tech complex are still performing, but is a meaningful rotation into real assets like gold and copper underway?
In our latest podcast episode, Alison Savas is joined by Portfolio Manager Graham Hay for a discussion about two key stock market sectors – technology and commodities.
As expectations around rate cuts have been meaningfully adjusted (catalysing a re-pricing of bonds), a rotation into real assets like gold and copper has begun.
However, parts of the mega cap tech complex are still performing well and market cap concentration remains at multi-decade highs.
Is it the time to retreat from tech stocks and re-think commodities?
Podcast key times:
The US economy has been incredibly resilient - can it keep powering ahead? 1:00
Meaningful moves in tech stocks: 5:00
Nvidia (NASDAQ: NVDA): 6:30
Tech opportunities in the current market cycle: 11:00
TSMC (NYSE: TSMC): 11:30
Qualcomm (NASDAQ: QCOM): 13:30
Commodities performance and outlook: 14:50
Teck Resources (NYSE: TECK): 20:00
Stock commentary in this content is illustrative only and should not be considered as recommendations to buy, hold, or sell any security.
More global investing insights
Visit antipodes.com and follow us on LinkedIn.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Antipodes' pragmatic value approach to investing in global equities aims to provide clients a smoother long-term wealth creation journey. We manage global long-only and long-short unit trusts, along with the Antipodes Global Shares (Quoted Managed Fund) active-ETF (ASX: AGX1). Through these vehicles, investors can access portfolios of attractively priced global businesses with strong long-term growth prospects. Antipodes was established in 2015. The investment team operates from offices in Sydney and London.
........
IMPORTANT INFORMATION:
All content in respect of the Antipodes Global Shares (Quoted Managed Fund) (ARSN 625 560 269), the Antipodes Global Fund – Long (ARSN 118 075 764), the Antipodes Global Fund (ARSN 087 719 515), and the Antipodes Emerging Markets (Managed Fund) (ARSN 096 451 393) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Funds and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice.
The information provided is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Funds, you should consider the current Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the Funds and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser. The Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the relevant Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.
Links to Product Disclosure Statement: IOF0045AU, WHT0057AU, IOF0203AU, WHT3997AU
Links to Target Market Determination: IOF0045AU, WHT0057AU, IOF0203AU, WHT3997AU
For historic TMD’s please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com
Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Funds. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this content. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.
Stock commentary is illustrative only.
2 topics
4 stocks mentioned
1 contributor mentioned
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
The 7 zombie companies lurking on the ASX 300
Livewire Markets
Equities
18 stocks backed by a fund that returned 42% in 12 months
Livewire Markets